LIMS Business Expert Joins Autoscribe Informatics’ Board

/in , /by

Jim Aurelio, who has a long and successful track record in the Lab Informatics business, has joined the Autoscribe Informatics’ Board of Directors. Aurelio, who is based in North America, will work closely with Autoscribe’s Executive team to strengthen strategic and operational plans with a key emphasis on serving the North American Markets. John Boother, […]

Read more →

JOHN MOCKLER ELECTED VICE PRESIDENT, INTERNATIONAL HUMAN RESOURCES

/in /by

BERWYN, PA – AMETEK, Inc. (NYSE: AME) today announced that its Board of Directors has elected John Mockler as Vice President, International Human Resources. “I am very pleased to announce that John has rejoined AMETEK in this important role,” comments David A. Zapico, AMETEK Chairman and Chief Executive Officer. “John’s extensive human resources background and […]

Read more →

JOE MILLER, VICE PRESIDENT OF CHEMISTRY AND STRATEGY

/in , , , , /by

Regis is proud to welcome Joe MIller, Ph.D. to the new senior leadership role of Vice President of Chemistry and Strategy. Joe will align our core chemical development groups: Process Research, Process Development, and Analytical Method Development into one cohesive customer-focused team and deliver great solutions to our customers. Joe received his Ph.D. in 1982 […]

Read more →

Robert Wicke Appointed as New CEO of Halo Labs

/in , /by

SAN FRANCISCO — Halo Labs, a venture-backed scientific instrumentation company developing high-throughput biopharmaceutical quality control tools, today announced the appointment of Robert Wicke as Chief Executive Officer. Robert is a seasoned executive with over 25 years of experience growing successful life science instrumentation companies through the commercialization of innovative new products and inorganic growth. Prior to joining Halo Labs, […]

Read more →

William Franco Joins VUV Analytics as Vice President of Engineering

/in , /by

Austin, TX – VUV Analytics, Inc., the leader in vacuum ultraviolet (VUV) absorption spectroscopy, has announced the addition of William Franco as Vice President of Engineering. Mr. Franco has an established track record of leading engineering teams at highly successful startups and larger companies, including LifeSize, TippingPoint, National Instruments, and Cisco.  Most recently, he was […]

Read more →

BD Appoints Simon Campion to Interventional Segment President

/in /by

FRANKLIN LAKES, N.J.– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.   Campion, 47, will report to Tom Polen, president of BD, and will be responsible for the global strategic, operational and commercial performance of the […]

Read more →

JH Technologies Welcomes Electron Microscope (EM) Sample Preparation Expert Jerome Pons

/in , , , /by

JH Technologies, leading distributor of optical and digital imaging systems, materials preparation, testing and analysis systems and metrology tools announces that Jerome Pons recently joined the company at its headquarters in Fremont, Calif. as senior imaging specialist. Mr. Pons brings nearly 20 years of experience in electron microscopy, including developing new techniques to improve efficiency […]

Read more →

William Muzek joins Lifecycle Biotechnologies as Business Development Manager

/in , /by

FORT WORTH, Texas Lifecycle Biotechnologies, a leading life science tools and services supplier, welcomes William “Will” Muzek as Business Development Manager. In this role, Mr. Muzek will lead the company-wide industrial strategic business development efforts to achieve strategic goals and to accelerate Lifecycle’s continued growth and expansion. With over 20 years in business development, Mr. […]

Read more →

Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new full-length single-cell mRNA sequencing application for the C1™ system that provides deep coverage and high sensitivity while reducing sample preparation costs by over 30%. Ideal for validation and further interrogation of new single-cell populations identified by ultra-high throughput methods, this new application expands the capability of the C1 to advance new single-cell discoveries. Because ultra-high throughput methods currently lack the coverage and sensitivity to go beyond cell identification and classification, researchers in the single-cell community have increasingly relied on full-length sequencing to confirm and characterize newly identified single-cell populations. To support this approach, Fluidigm researchers collaborated with New England Biolabs® (NEB®) to develop a more affordable full-length single-cell mRNA sequencing workflow for use with C1. Researchers can easily upgrade their C1 systems and download the new NEBNext® full-length cDNA Synthesis scripts and protocols through Script Hub™ for immediate use with C1 96 mRNA sequencing and C1 Open App™ 96 integrated fluidic circuits. “NEB recently launched its NEBNext Single Cell/Low Input RNA Library Prep Kit, which enables high sensitivity and reliability of transcript detection, and is pleased to be working with Fluidigm to support its use on the C1 system,” said Fiona Stewart, Next Generation Sequencing Portfolio Manager at NEB. “Single-cell biology is an important and growing area of life science research, with great potential in many fields, including cancer and neurobiology. We are excited that the combination of NEB’s and Fluidigm’s technologies will better meet the needs of researchers working in this area.” “We are pleased to offer the single-cell community with a more cost-effective method to validate and characterize ultra-high throughput studies,” said Chris Linthwaite, President and CEO of Fluidigm. “By bringing together the advantages of microfluidics technology with optimized chemistries from NEB, we believe this winning combination will enable researchers to further expand our overall understanding of health and disease at single-cell resolution.” About Fluidigm Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm, the Fluidigm logo, C1, C1 Open App, and Script Hub are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Forward-Looking Statement for Fluidigm This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of single-cell biology research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including the Fluidigm Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

/in /by

Didier Hirsch to Retire Oct. 31 Robert W. McMahon to Become Chief Financial Officer SANTA CLARA, Calif– Agilent Technologies Inc. (NYSE:A) today announced that Didier Hirsch, senior vice president and chief financial officer, has decided to retire on Oct 31, 2018. The company has appointed Robert W. McMahon, currently chief financial officer, Hologic, Inc., as his successor. McMahon will join Agilenton August 3, as senior vice […]

Read more →